Drugs.com - Clinical Trials

SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis

OSAKA, Japan, March 13, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral presentation at the Conference of...

Mar 18, 2025 - 07:11
 0
SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
OSAKA, Japan, March 13, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral presentation at the Conference of...
Read More

Tags:

Previous Article

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Po...

Next Article

8 Luxury Cars Of 2025 That Burn Rubber & Spark Joy

Related Posts

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Zydus Announces USFDA Orphan Drug Designation to Usnofl...

Feb 9, 2025  0

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Depemokimab Delivers Clinically Meaningful and Statisti...

Mar 3, 2025  0

Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function

Humanetics Corporation Announces Positive Phase 2 Clini...

Feb 9, 2025  0